VEGFA and neoplasm: In our study, TTAC-0001, a novel fully human anti-VEGFR-2/KDR monoclonal antibody that blocks VEGF/VEGFR-2 signaling, showed selective tumor targeting that lasted at least 6 days, an anti-angiogenic effect to inhibit neovascularization, and anti-tumor efficacy.